![Bernhard R. M. Ehmer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bernhard R. M. Ehmer
Presidente en BIOTEST AG .
Fortuna: 24 791 $ al 31/12/2024
Perfil
Bernhard R.
M.
Ehmer is currently the Chairman-Supervisory Board at Biotest AG, an Independent Non-Executive Director at Achilles Therapeutics Plc, an Independent Member-Supervisory Board at Affimed NV, and a Member-Supervisory Board at Affimed GmbH.
Previously, he held positions such as Chief Executive Officer & Managing Director at Biopheresis GmbH and BioPheresis Technologies, Inc., President & Chief Executive Officer at Neovii Biotech GmbH, Chairman-Management Board at Biotest AG, Chairman at Symphogen A, Director at ADMA Biologics, Inc., Director at Aton SA, Managing Director & Senior Vice President at ImClone Systems International GmbH, VP, Head-Strategic Planning & Alliance Management at Merck KGaA, Head-Clinical Research & Development Operations at Merck KGaA, and Head-Therapeutics & Medical Operations at Boehringer Mannheim GmbH.
He also served as President at ImClone Systems Corp.
Dr. Ehmer obtained his undergraduate degree from Ruprecht-Karls-Universität Heidelberg and Ludwig-Maximilians-Universität München in 1982.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AFFIMED N.V.
0.14% | 15/03/2024 | 20 833 ( 0.14% ) | 24 791 $ | 31/12/2024 |
Cargos activos de Bernhard R. M. Ehmer
| Empresas | Cargo | Inicio |
|---|---|---|
| AFFIMED N.V. | Director/Miembro de la Junta | 21/01/2016 |
| ACHILLES THERAPEUTICS PLC | Director/Miembro de la Junta | 04/05/2022 |
| BIOTEST AG | Presidente | 05/05/2022 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Miembro de la Junta | 01/01/2016 |
Antiguos cargos conocidos de Bernhard R. M. Ehmer.
| Empresas | Cargo | Fin |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Presidente | 01/06/2020 |
| BIOTEST AG | Director Ejecutivo | 01/04/2019 |
| ADMA BIOLOGICS, INC. | Director/Miembro de la Junta | 15/02/2018 |
| ImClone Systems Corp. | Presidente | 01/10/2014 |
ImClone Systems International GmbH
 ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/2012 |
Formación de Bernhard R. M. Ehmer.
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
| Ludwig-Maximilians-Universität München | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 6 |
|---|---|
| ATON | Health Technology |
| ADMA BIOLOGICS, INC. | Health Technology |
| MERCK KGAA | Health Technology |
| BIOTEST AG | Health Technology |
| AFFIMED N.V. | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 8 |
|---|---|
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
BioPheresis Technologies, Inc.
 BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
| ImClone Systems Corp. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
Biopheresis GmbH
 Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The company is based in Heidelberg, Germany. | Commercial Services |
| Boehringer Mannheim GmbH |
- Bolsa de valores
- Insiders
- Bernhard R. M. Ehmer
